Summary of Study ST000120

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000107. The data can be accessed directly via it's Project DOI: 10.21228/M8MK57 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files
Study IDST000120
Study TitleDisruption of Zinc homeostasis can impair maternal glucocorticoid metabolism: consequences on the developing fetus
Study Typesteroid panel in pregnant rats
Study SummarySteroids play a broad and vital role in regulation of gene expression, secondary sexual characteristics, maturation, reproduction, and neurological functions; but an imbalance in steroid metabolism is also linked to development and progression of many diseases including autism. Prenatal stress of different nature has been demonstrated to affect both the mother and the offspring. Adverse nutritional conditions during gestation can impair the maternal hypothalamic-pituitary-adrenal axis (HPA) and expose the fetus to high levels of glucocorticoids (GC). Evenwhen GC are required for normal brain development; an increased exposure of the fetus to GC as a consequence of prenatal stress can affect fetal hypothalamic-pituitary-gonad axis (HPG) development, impair neurogenesis, and have a long term impact on the offspring’s mental health. Decreased zinc availability can occur during pregnancy as a consequence of different conditions (nutritional deficiency, infections, diabetes, alcohol consumption, and exposure to certain toxicants). Importantly, several of these gestational conditions have been linked to autism. In fact, alterations in maternal zinc homeostasis upon exposure to select environmental stressors (e.g. the phthalate plasticizer bis-2-ethylhexyl phthalate (DEHP)) that have become increasingly common since the industrial revolution may underlie the recent rise in the incidence of autism.Alterations in maternal zinc homeostasis could expose the fetus to high GC concentrations secondary to a high maternal GC production and/or to a decreased capacity of the placenta to metabolize GC to inactive metabolites. The overall goal of this proposal is to investigate if alterations in zinc homeostasis during gestation triggered by either a marginal zinc nutrition or exposure to an environmental pollutant (the phthalate plasticizer bis-2-ethylhexyl phthalate (DEHP)) can impair maternal and fetal endocrine signaling leading to impaired fetal brain development.
Institute
University of California, Davis
DepartmentNutrition
LaboratoryGaikwad Lab
Last NameKucera
First NameHeidi
Emailhrkucera@ucdavis.edu
Submit Date2014-09-30
Num Groups4
Total Subjects270 tissue/fluid samples
Raw Data AvailableNo
Analysis Type DetailLC-MS
Release Date2014-09-30
Release Version1
Heidi Kucera Heidi Kucera
https://dx.doi.org/10.21228/M8MK57
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR000107
Project DOI:doi: 10.21228/M8MK57
Project Title:Disruption of Zinc homeostasis can impair maternal glucocorticoid metabolism: consequences on the developing fetus
Project Type:Pilot and Feasibility Projects
Project Summary:Steroids play a broad and vital role in regulation of gene expression, secondary sexual characteristics, maturation, reproduction, and neurological functions; but an imbalance in steroid metabolism is also linked to development and progression of many diseases including autism. Prenatal stress of different nature has been demonstrated to affect both the mother and the offspring. Adverse nutritional conditions during gestation can impair the maternal hypothalamic-pituitary-adrenal axis (HPA) and expose the fetus to high levels of glucocorticoids (GC). Evenwhen GC are required for normal brain development; an increased exposure of the fetus to GC as a consequence of prenatal stress can affect fetal hypothalamic-pituitary-gonad axis (HPG) development, impair neurogenesis, and have a long term impact on the offspring’s mental health. Decreased zinc availability can occur during pregnancy as a consequence of different conditions (nutritional deficiency, infections, diabetes, alcohol consumption, and exposure to certain toxicants). Importantly, several of these gestational conditions have been linked to autism. In fact, alterations in maternal zinc homeostasis upon exposure to select environmental stressors (e.g. the phthalate plasticizer bis-2-ethylhexyl phthalate (DEHP)) that have become increasingly common since the industrial revolution may underlie the recent rise in the incidence of autism.Alterations in maternal zinc homeostasis could expose the fetus to high GC concentrations secondary to a high maternal GC production and/or to a decreased capacity of the placenta to metabolize GC to inactive metabolites. The overall goal of this proposal is to investigate if alterations in zinc homeostasis during gestation triggered by either a marginal zinc nutrition or exposure to an environmental pollutant (the phthalate plasticizer bis-2-ethylhexyl phthalate (DEHP)) can impair maternal and fetal endocrine signaling leading to impaired fetal brain development.
Institute:University of California, Davis
Department:Nutrition
Laboratory:Gaikwad Lab
Last Name:Gaikwad
First Name:Nilesh
Email:nwgaikwad@ucdavis.edu
Phone:530-752-2906
Funding Source:NIH 1U24DK097154 ;  PI Fiehn, Oliver  ; UC Davis WEST COAST CENTRAL COMPREHENSIVE METABOLOMICS RESOURCE CORE (WC3MRC)

Subject:

Subject ID:SU000139
Subject Type:Animal
Subject Species:Rattus norvegicus
Taxonomy ID:10116
Genotype Strain:Sprague-Dawley Rats
Age Or Age Range:adult
Weight Or Weight Range:200-225 g
Gender:Female
Species Group:Mammal

Factors:

Subject type: Animal; Subject species: Rattus norvegicus (Factor headings shown in green)

mb_sample_id local_sample_id Tissue/Fluid Treatment
SA00623439 control Adrenal DamAdrenal gland Control
SA00623540 control Adrenal DamAdrenal gland Control
SA0062361 control Adrenal DamAdrenal gland Control
SA00623728 control Adrenal DamAdrenal gland Control
SA00623827 control Adrenal DamAdrenal gland Control
SA0062393 control Adrenal DamAdrenal gland Control
SA0062408 control Adrenal DamAdrenal gland Control
SA0062419 control Adrenal DamAdrenal gland Control
SA00624212 control Adrenal DamAdrenal gland Control
SA00624318 C+D Adrenal DamAdrenal gland Control + DEHP
SA00624426 C+D Adrenal DamAdrenal gland Control + DEHP
SA00624542 C+D Adrenal DamAdrenal gland Control + DEHP
SA00624631 C+D Adrenal DamAdrenal gland Control + DEHP
SA00624736 C+D Adrenal DamAdrenal gland Control + DEHP
SA00624829 C+D Adrenal DamAdrenal gland Control + DEHP
SA00624910 MZD Adrenal DamAdrenal gland Marginal Zinc deficient
SA00625011 MZD Adrenal DamAdrenal gland Marginal Zinc deficient
SA0062515 MZD Adrenal DamAdrenal gland Marginal Zinc deficient
SA00625241 MZD Adrenal DamAdrenal gland Marginal Zinc deficient
SA00625332 MZD Adrenal DamAdrenal gland Marginal Zinc deficient
SA00625419 MZD Adrenal DamAdrenal gland Marginal Zinc deficient
SA00625514 MZD Adrenal DamAdrenal gland Marginal Zinc deficient
SA00625625 MZ+D Adrenal DamAdrenal gland Marginal Zinc deficient + DEHP
SA00625737 MZ+D Adrenal DamAdrenal gland Marginal Zinc deficient + DEHP
SA00625823 MZ+D Adrenal DamAdrenal gland Marginal Zinc deficient + DEHP
SA00625933 MZ+D Adrenal DamAdrenal gland Marginal Zinc deficient + DEHP
SA00626016 MZ+D Adrenal DamAdrenal gland Marginal Zinc deficient + DEHP
SA0062612 MZ+D Adrenal DamAdrenal gland Marginal Zinc deficient + DEHP
SA0062624 MZ+D Adrenal DamAdrenal gland Marginal Zinc deficient + DEHP
SA00626322 MZ+D Adrenal DamAdrenal gland Marginal Zinc deficient + DEHP
SA0062641 control AFAmniotic fluid Control
SA00626528 control AFAmniotic fluid Control
SA00626640 control AFAmniotic fluid Control
SA0062673 control AFAmniotic fluid Control
SA00626827 control AFAmniotic fluid Control
SA00626939 control AFAmniotic fluid Control
SA00627012 control AFAmniotic fluid Control
SA0062719 control AFAmniotic fluid Control
SA0062728 control AFAmniotic fluid Control
SA00627326 C+D AFAmniotic fluid Control + DEHP
SA00627431 C+D AFAmniotic fluid Control + DEHP
SA00627536 C+D AFAmniotic fluid Control + DEHP
SA00627618 C+D AFAmniotic fluid Control + DEHP
SA00627742 C+D AFAmniotic fluid Control + DEHP
SA00627829 C+D AFAmniotic fluid Control + DEHP
SA00627932 MZD AFAmniotic fluid Marginal Zinc deficient
SA0062805 MZD AFAmniotic fluid Marginal Zinc deficient
SA00628141 MZD AFAmniotic fluid Marginal Zinc deficient
SA00628211 MZD AFAmniotic fluid Marginal Zinc deficient
SA00628310 MZD AFAmniotic fluid Marginal Zinc deficient
SA00628414 MZD AFAmniotic fluid Marginal Zinc deficient
SA00628519 MZD AFAmniotic fluid Marginal Zinc deficient
SA00628633 MZ+D AFAmniotic fluid Marginal Zinc deficient + DEHP
SA00628737 MZ+D AFAmniotic fluid Marginal Zinc deficient + DEHP
SA00628825 MZ+D AFAmniotic fluid Marginal Zinc deficient + DEHP
SA0062894 MZ+D AFAmniotic fluid Marginal Zinc deficient + DEHP
SA00629016 MZ+D AFAmniotic fluid Marginal Zinc deficient + DEHP
SA00629122 MZ+D AFAmniotic fluid Marginal Zinc deficient + DEHP
SA00629223 MZ+D AFAmniotic fluid Marginal Zinc deficient + DEHP
SA0062932 MZ+D AFAmniotic fluid Marginal Zinc deficient + DEHP
SA00632427 control Brain FemaleFetal Female brain Control
SA00632540 control Brain FemaleFetal Female brain Control
SA00632639 control Brain FemaleFetal Female brain Control
SA0063271 control Brain FemaleFetal Female brain Control
SA00632812 control Brain FemaleFetal Female brain Control
SA0063298 control Brain FemaleFetal Female brain Control
SA00633028 control Brain FemaleFetal Female brain Control
SA0063319 control Brain FemaleFetal Female brain Control
SA0063323 control Brain FemaleFetal Female brain Control
SA00633326 C+D Brain FemaleFetal Female brain Control + DEHP
SA00633442 C+D Brain FemaleFetal Female brain Control + DEHP
SA00633536 C+D Brain FemaleFetal Female brain Control + DEHP
SA00633629 C+D Brain FemaleFetal Female brain Control + DEHP
SA00633731 C+D Brain FemaleFetal Female brain Control + DEHP
SA00633818 C+D Brain FemaleFetal Female brain Control + DEHP
SA00633919 MZD Brain FemaleFetal Female brain Marginal Zinc deficient
SA00634041 MZD Brain FemaleFetal Female brain Marginal Zinc deficient
SA0063415 MZD Brain FemaleFetal Female brain Marginal Zinc deficient
SA00634214 MZD Brain FemaleFetal Female brain Marginal Zinc deficient
SA00634332 MZD Brain FemaleFetal Female brain Marginal Zinc deficient
SA00634410 MZD Brain FemaleFetal Female brain Marginal Zinc deficient
SA00634511 MZD Brain FemaleFetal Female brain Marginal Zinc deficient
SA00634625 MZ+D Brain FemaleFetal Female brain Marginal Zinc deficient + DEHP
SA00634733 MZ+D Brain FemaleFetal Female brain Marginal Zinc deficient + DEHP
SA00634837 MZ+D Brain FemaleFetal Female brain Marginal Zinc deficient + DEHP
SA00634923 MZ+D Brain FemaleFetal Female brain Marginal Zinc deficient + DEHP
SA0063502 MZ+D Brain FemaleFetal Female brain Marginal Zinc deficient + DEHP
SA0063514 MZ+D Brain FemaleFetal Female brain Marginal Zinc deficient + DEHP
SA00635216 MZ+D Brain FemaleFetal Female brain Marginal Zinc deficient + DEHP
SA00635322 MZ+D Brain FemaleFetal Female brain Marginal Zinc deficient + DEHP
SA00629439 control Liver FFetal Female Liver Control
SA00629540 control Liver FFetal Female Liver Control
SA0062963 control Liver FFetal Female Liver Control
SA00629728 control Liver FFetal Female Liver Control
SA0062981 control Liver FFetal Female Liver Control
SA0062998 control Liver FFetal Female Liver Control
SA0063009 control Liver FFetal Female Liver Control
SA00630127 control Liver FFetal Female Liver Control
SA00630212 control Liver FFetal Female Liver Control
SA00630329 C+D Liver FFetal Female Liver Control + DEHP
Showing page 1 of 3     Results:    1  2  3  Next     Showing results 1 to 100 of 270

Collection:

Collection ID:CO000123
Collection Summary:-
Sample Type:Adrenal gland

Treatment:

Treatment ID:TR000141

Sample Preparation:

Sampleprep ID:SP000136
Sampleprep Summary:Methanol: Water Extraction
Sampleprep Protocol Filename:NIH_WCMC_Oteiza_Method_GaikwadLab__SteroidAnalysis_2013-14.pdf
Processing Method:Homogenization and Solvent Removal w/ Speed Vac
Processing Storage Conditions:On Ice
Extraction Method:1:1 Methanol: Water
Extract Concentration Dilution:100mg or 1ml per 4ml 1:1 MeOH:H2O
Extract Storage:-80C
Sample Resuspension:150ul CH3OH/H2O
Organ:Sprague-Dawley Maternal: Adrenal, liver, placenta, amniotic fluid Sprague-Dawley Fetal: Male and female brain, male and female liver

Combined analysis:

Analysis ID AN000202
Analysis type MS
Chromatography type Reversed phase
Chromatography system Waters Acquity
Column Waters Acquity HSS T3 (150 x 2.1mm,1.8um)
MS Type ESI
MS instrument type Triple quadrupole
MS instrument name Waters Xevo-TQ
Ion Mode POSITIVE
Units pmole/g

Chromatography:

Chromatography ID:CH000134
Chromatography Summary:Targeted UPLC-MS/MS
Instrument Name:Waters Acquity
Column Name:Waters Acquity HSS T3 (150 x 2.1mm,1.8um)
Flow Gradient:0-2 min 100% A (Water 0.1% formic acid) 0% B (CH3CN 0.1 % formic acid), 2-4 min 80% A, 4-9mins 45% A, 9-11 mins 20% A, 11-12 mins 100% A
Flow Rate:0.15 ml/min
Sample Injection:10ul
Solvent A:100% water; 0.1% formic acid
Solvent B:100% acetonitrile; 0.1% formic acid
Analytical Time:12 mins
Chromatography Type:Reversed phase

MS:

MS ID:MS000165
Analysis ID:AN000202
Instrument Name:Waters Xevo-TQ
Instrument Type:Triple quadrupole
MS Type:ESI
MS Comments:ESI MS and MS/MS
Ion Mode:POSITIVE
Capillary Voltage:3.0 kV
Collision Gas:N2
Ionization:Electrospray Ionization
Source Temperature:150C
Desolvation Gas Flow:600 L/h
Desolvation Temperature:350C
Acquisition Parameters File:CS_WCMC_Oteiza
Processing Parameters File:CS_WCMC_Oteiza
  logo